Gastroenterologists raise concerns over biosimilars

A law that may allow a pharmacist to substitute a biologic for a biosimilar without clinician input is causing concern among gastroenterologists.

Professor Jane Andrews, chair of the Australian Inflammatory Bowel Disease Association (AIBDA), says there is little data to support the safety and long-term efficacy of switching between an originator molecule and its biosimilar.

The exception is